With the Fed likely to be lowering rates until next summer, now is the time to load up on five of our favorite blue-chip ...

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment ...

Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff:31 (97%) were ...

Scott Galovan noted a "decline of over 20%" in hyaluronic acid injections and intravenous infusion product lines in fiscal Q3 ...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2025, along with recent ...

Fiserv (FI) leads decliners with a 49% drop, driven by leadership turmoil, weak consumer spending, and a downgraded quant ...

Baxter International stock hits 20-year low, but undervaluation and new CEO strategy offer turnaround potential.

Total revenue for the quarter ended September 30, 2025 was $134.2 million, up 12% from $119.8 million in the same period of 2024. This growth and operational momentum was driven primarily by continued ...

DelveInsight's Chronic Progressive Multiple Sclerosis Market Insights report includes a comprehensive understanding of current treatment practices, chronic progressive multiple sclerosis emerging ...

Hospitalized patients with diabetes require specialized management to reduce readmission rates and complications. Newer ...

On one of the coldest mornings ever in Florida, a young green sea turtle flailed through freezing surf. Too stunned to swim, ...

TG Therapeutics, Inc. (NASDAQ: TGTX) Q3 2025 Earnings Call Transcript November 3, 2025 TG Therapeutics, Inc. beats earnings ...